A Phase 3 interventional study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis (PBC), sponsored by Xijing Hospital of Digestive Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Xijing Hospital of Digestive Diseases · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary — 7 open to participants now, 9 under way, 8 of them phase 3. Fenofibrate · Liver Cirrhosis, Biliary.
Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2024, is one of 6 in phase 3, and was the 10th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →7 of the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary are open now, in 1 country. Recruiting first, the newest first:
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
By country, each count listing its studies:
Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 9
First in 2011; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 117 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 4 most frequent:
Xijing Hospital of Digestive Diseases is the lead sponsor of 81 studies on the registry; 23 are open to participants now.
12 studies in Liver Cirrhosis, Biliary by Xijing Hospital of Digestive Diseases: 7 open now, 8 under way, 7 of them phase 3. Of 1 finished, 0 (0%) have results posted.
Among the 12 studies in Liver Cirrhosis, Biliary by Xijing Hospital of Digestive Diseases, this one is the 4th largest by planned enrollment, is one of 2 that started in 2024, is one of 8 in phase 3, and was the 9th registered.
Xijing Hospital of Digestive Diseases’s Liver Cirrhosis, Biliary studies by the year they started, since 2016.
1 of the studies testing fenofibrate in Liver Cirrhosis, Biliary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06365424Phase 3Xijing Hospital of Digestive DiseasesFenofibrate in Patients With Primary Biliary Cholangitis (PBC) | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, from their registry updates:
Among Xijing Hospital of Digestive Diseases’s 12 in Liver Cirrhosis, Biliary:
This tab as a report to print or save as PDF → With an account.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: Fenofibrate 200 mg Capsules
Drug: Fenofibrate in Combination With Ursodeoxycholic Acid
Drug pages: FenofibrateStudies of FenofibrateFenofibrate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Ursodeoxycholic AcidStudies of Ursodeoxycholic AcidUrsodeoxycholic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Experimental: Fenofibrate 200 mg Capsules
Treatment emergent adverse events (TEAEs)
Time frame: Through study completion, up to 120 Months
Death
Occurrence of overall death
Time frame: 120 months
Liver transplantation
Occurrence of overall liver transplantation
Time frame: 120 months
Normalization of ALP
Proportion of subjects with normalization of ALP
Time frame: 120 months
Started Jan 2024 (actual). Primary completion is estimated for Dec 2035, 143 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fenofibrate · Ursodeoxycholic Acid
Xijing Hospital of Digestive Diseases